EYENOVIA INCO. reduced its risk exposure resulting in an upgrade to Slightly Positive
EYENOVIA INCO. (US), a company active in the Pharmaceuticals industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date October 12, 2021, the closing price was USD 5.51 and its potential was estimated at USD 6.31.Eyenovia is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing the company's patented piezo-print delivery technology, branded the Optejet?. The company's MicroStat is a fixed combination formulation of phenylephrine-tropicamide for mydriasis (pupil dilation). MicroPine is a topical therapy for the treatment of progressive myopia. MicroProst is a latanoprost formulation for lowering intraocular pressure in patients with ocular hypertension, primary open angle glaucoma, and chronic angle closure glaucoma. MicroTears is the company's over-the-counter product candidate for hyperemia (red eye), pruritis (itch) and dry eye.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.